Self-expanding Nitinol Stents of High vs. Low Chronic Outward Force in De-novo Femoropopliteal Occlusive Arterial Lesions
NCT ID: NCT03097679
Last Updated: 2020-02-20
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
86 participants
Study Classification
INTERVENTIONAL
Study Start Date
2015-10-01
Study Completion Date
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The objective of the BIOFLEX-COF trial is to investigate differences in formation of intimal hyperplasia at one and two years after implantation of nitinol-stents with high vs. low COF in de-novo femoropopliteal occlusive lesions in patients with symptomatic peripheral arterial disease.
The BIOFLEX-COF trial is a prospective, randomized controlled trial. 80 subjects will be enrolled and randomly assigned to either a high COF group (LifeStent Vascular Stent) or low COF group (Pulsar).
The BIOFLEX-COF trial is a prospective, randomized controlled trial. 80 subjects will be enrolled and randomly assigned to either a high COF group (LifeStent Vascular Stent) or low COF group (Pulsar).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Post-Market Study of ZENFLEX Pro Stent for Femoropopliteal Artery Lesions
NCT07049120
Peripheral Arterial Disease
NOT_YET_RECRUITING
NA
DURABILITY-200: EverFlex 200mm Long Nitinol Stents in TASC C&D Femoropopliteal Lesions
NCT00637741
Peripheral Vascular Disease
Intermittent Claudication
Critical Limb Ischemia
COMPLETED
PHASE4
Paclitaxel-coated Peripheral Stents Used in the Treatment of Femoropopliteal Stenoses
NCT02936622
Peripheral Arterial Disease (PAD)
COMPLETED
NA
Multicentric Non-randomized Investigation of RESISTANT Camouflage Stent-system
NCT02011984
Peripheral Artery Disease
UNKNOWN
Post-Market Clinical Follow-Up of S.M.A.R.T. Family of Stents in Treating Iliac and Femoropopliteal Artery Disease
NCT07338890
Superficial Femoral Artery Stenosis
Iliac Artery Stenosis
Popliteal Artery Stenosis
NOT_YET_RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Self-expanding nitinol stents must be oversized at least by a minimal amount to ensure contact with the vessel wall and prevent migration. Once the stent is deployed it exerts a continuous force upon the vascular wall, termed chronic outward force (COF). Data about COF and neointimal hyperplasia in humans are currently lacking. Some animal studies, though, found a markedly increased neointimal hyperplasia in stents with high oversizing and thus high COF. The objective of the BIOFLEX-COF trial is to investigate differences in formation of intimal hyperplasia at one and two years after implantation of nitinol-stents with high vs. low COF in de-novo femoropopliteal occlusive lesions in patients with symptomatic peripheral arterial disease.
The BIOFLEX-COF trial is a prospective, randomized controlled trial. 80 subjects will be enrolled and randomly assigned to either a high COF group (LifeStent Vascular Stent) or low COF group (Pulsar). Diameter of implanted stents will be measured at every two millimetres along the stent axis on DICOM images of the respective completion angiography using image processing software.
The scheduled time for recruitment is 2 years. There will be two follow-up evaluations at 12 and 24 months.
Primary endpoint is the amount of in-stent neointima at one year, assessed by contrast-enhanced CT angiography (CTA). Secondary objectives are the amount of in-stent neointima at two years, device- and procedure-related adverse events and target lesion revascularisation (TLR) rate.
In the control examinations stent diameter and true lumen diameter will be measured on DICOM images every two millimetres along the stent axis to quantify the relative amount of in-stent restenosis.
The present study is challenging in that it compares two different self-expanding nitinol-stents head-to-head against each other. To optimize the power of this study, both clinical TLR and binary re-stenosis at Colour flow Doppler Ultrasound were dropped as primary endpoints. Instead the amount of neointima inside the stent accessed by CTA was selected as outcome parameter.
The study differs further from similar previous trials in its generous inclusions criteria. This was done in effort to perform the trial on a patient sample that closely represents real-world patients of a specialised endovascular centre.
The BIOFLEX-COF trial is a prospective, randomized controlled trial. 80 subjects will be enrolled and randomly assigned to either a high COF group (LifeStent Vascular Stent) or low COF group (Pulsar). Diameter of implanted stents will be measured at every two millimetres along the stent axis on DICOM images of the respective completion angiography using image processing software.
The scheduled time for recruitment is 2 years. There will be two follow-up evaluations at 12 and 24 months.
Primary endpoint is the amount of in-stent neointima at one year, assessed by contrast-enhanced CT angiography (CTA). Secondary objectives are the amount of in-stent neointima at two years, device- and procedure-related adverse events and target lesion revascularisation (TLR) rate.
In the control examinations stent diameter and true lumen diameter will be measured on DICOM images every two millimetres along the stent axis to quantify the relative amount of in-stent restenosis.
The present study is challenging in that it compares two different self-expanding nitinol-stents head-to-head against each other. To optimize the power of this study, both clinical TLR and binary re-stenosis at Colour flow Doppler Ultrasound were dropped as primary endpoints. Instead the amount of neointima inside the stent accessed by CTA was selected as outcome parameter.
The study differs further from similar previous trials in its generous inclusions criteria. This was done in effort to perform the trial on a patient sample that closely represents real-world patients of a specialised endovascular centre.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Stent Restenosis
Intimal Hyperplasia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
low COF-group
The low COF-group receives a thin-strut stent (Pulsar, Biotronik AG, Bülach, Switzerland) with minimal oversizing (according to manufacturer's Instructions For Use)
Group Type
ACTIVE_COMPARATOR
Pulsar Stent
Intervention Type
DEVICE
Percutane transluminal stent angioplasty with a Pulsar Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.
high COF-group
The high COF-group receives a stiffer-stent (Lifestent Flexstar, Bard Peripheral Vascular Inc., Tempe, AZ, USA) with maximal oversizing (according to manufacturer's Instructions For Use).
Group Type
ACTIVE_COMPARATOR
LifeStent Flexstar Vascular Stent
Intervention Type
DEVICE
Percutane transluminal stent angioplasty with a LifeStent Flexstar Vascular Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pulsar Stent
Percutane transluminal stent angioplasty with a Pulsar Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.
Intervention Type
DEVICE
LifeStent Flexstar Vascular Stent
Percutane transluminal stent angioplasty with a LifeStent Flexstar Vascular Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Patient related:
1. Subject (or their legal guardian) has read, understood and provided written informed consent, which has been reviewed and approved by the Institutional Review Board.
2. At least 18 years of age.
3. Male, infertile female or female participants of child bearing potential practicing an acceptable method of birth control with a negative pregnancy test within 7-days prior to study procedure.
4. Projected life expectancy of greater than two years.
5. The ability to comply with protocol follow-up requirements and required testing.
Clinical:
1. Lifestyle-limiting claudication or CLI (meeting angiographic entry criteria) affecting a lower extremity (Rutherford stages 2-5). Patients with Rutherford stage 2 are only eligible after unsuccessful conventional and/or medicamentous therapy.
2. Resting ankle-brachial index (ABI) ≤ 0.8 in the study limb.
3. Inflow lesion - if present - has been treated successfully (inflow treatment in same procedure permissible)
Angiographic and Lesion Requirements (assessed intraoperatively):
1. TASC A-D lesions from stenoses /occlusions ≤ 35cm.
2. Popliteal artery is patent 5 cm proximal to the radiographic knee joint line.
3. Reference diameter of 4.0 - 7.0 mm in proximal and distal treatment segments within the SFA.
4. Patent SFA orifice (the proximal 5 mm after femoral bifurcation).
5. At least one patent (\<50% stenotic) inflow vessel present, proven angiographically. Study eligibility is given when inflow lesion has been treated successfully (inflow treatment in same procedure permissible). Successful treatment of inflow lesion is defined as \<50% stenosis without death or severe vascular complication.
6. At least one patent (\<50% stenotic)tibial artery runoff to the ankle present, proven angiographically. Study eligibility is given when runoff vessel lesion has been treated successfully (inflow treatment in same procedure permissible). Successful treatment of inflow lesion is defined as \<50% stenosis without death or severe vascular complication.Guidewire has successfully traversed lesion and is within the true lumen of the distal vessel.
1. Subject (or their legal guardian) has read, understood and provided written informed consent, which has been reviewed and approved by the Institutional Review Board.
2. At least 18 years of age.
3. Male, infertile female or female participants of child bearing potential practicing an acceptable method of birth control with a negative pregnancy test within 7-days prior to study procedure.
4. Projected life expectancy of greater than two years.
5. The ability to comply with protocol follow-up requirements and required testing.
Clinical:
1. Lifestyle-limiting claudication or CLI (meeting angiographic entry criteria) affecting a lower extremity (Rutherford stages 2-5). Patients with Rutherford stage 2 are only eligible after unsuccessful conventional and/or medicamentous therapy.
2. Resting ankle-brachial index (ABI) ≤ 0.8 in the study limb.
3. Inflow lesion - if present - has been treated successfully (inflow treatment in same procedure permissible)
Angiographic and Lesion Requirements (assessed intraoperatively):
1. TASC A-D lesions from stenoses /occlusions ≤ 35cm.
2. Popliteal artery is patent 5 cm proximal to the radiographic knee joint line.
3. Reference diameter of 4.0 - 7.0 mm in proximal and distal treatment segments within the SFA.
4. Patent SFA orifice (the proximal 5 mm after femoral bifurcation).
5. At least one patent (\<50% stenotic) inflow vessel present, proven angiographically. Study eligibility is given when inflow lesion has been treated successfully (inflow treatment in same procedure permissible). Successful treatment of inflow lesion is defined as \<50% stenosis without death or severe vascular complication.
6. At least one patent (\<50% stenotic)tibial artery runoff to the ankle present, proven angiographically. Study eligibility is given when runoff vessel lesion has been treated successfully (inflow treatment in same procedure permissible). Successful treatment of inflow lesion is defined as \<50% stenosis without death or severe vascular complication.Guidewire has successfully traversed lesion and is within the true lumen of the distal vessel.
Exclusion Criteria
1. Pregnant and/or breast-feeding women.
2. Lesion length \> 35 cm.
3. Flow-limiting occlusive disease of inflow and / or outflow arteries that cannot be treated sufficiently.
4. Previous stenting or femoral bypass surgery in the target vessel.
5. Clinical relevant aneurysmatic disease of the abdominal aorta, ipsilateral femoral arteries or arteries of the knee.
6. Rutherford stage 0, 1 or 6
7. Non-atherosclerotic disease resulting in occlusion (e.g., embolism, Buerger's disease, vasculitis).
8. Septicaemia.
9. Ischemic stroke within the last three months.
10. Any previously known coagulation disorder, including hypercoagulability
11. Morbid obesity or operative scarring that precludes percutaneous approach (physician's discretion).
12. Contraindication to anticoagulation or antiplatelet therapy.
13. Known allergy to medication or contrast media used in this trial, if pre-treatment is not possible (physician's discretion).
14. Known allergies to stent components (especially Nickel).
15. Severe calcification of the target lesion.
16. Current participation in another clinical research trial, that has not reached its primary endpoint.
17. The patient is institutionalized based on a legal verdict.
2. Lesion length \> 35 cm.
3. Flow-limiting occlusive disease of inflow and / or outflow arteries that cannot be treated sufficiently.
4. Previous stenting or femoral bypass surgery in the target vessel.
5. Clinical relevant aneurysmatic disease of the abdominal aorta, ipsilateral femoral arteries or arteries of the knee.
6. Rutherford stage 0, 1 or 6
7. Non-atherosclerotic disease resulting in occlusion (e.g., embolism, Buerger's disease, vasculitis).
8. Septicaemia.
9. Ischemic stroke within the last three months.
10. Any previously known coagulation disorder, including hypercoagulability
11. Morbid obesity or operative scarring that precludes percutaneous approach (physician's discretion).
12. Contraindication to anticoagulation or antiplatelet therapy.
13. Known allergy to medication or contrast media used in this trial, if pre-treatment is not possible (physician's discretion).
14. Known allergies to stent components (especially Nickel).
15. Severe calcification of the target lesion.
16. Current participation in another clinical research trial, that has not reached its primary endpoint.
17. The patient is institutionalized based on a legal verdict.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Vienna
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alexander Wressnegger
Dr.med.univ.
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical University of Vienna
Vienna, , Austria
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Austria
References
Explore related publications, articles, or registry entries linked to this study.
Lammer J, Zeller T, Hausegger KA, Schaefer PJ, Gschwendtner M, Mueller-Huelsbeck S, Rand T, Funovics M, Wolf F, Rastan A, Gschwandtner M, Puchner S, Beschorner U, Ristl R, Schoder M. Sustained benefit at 2 years for covered stents versus bare-metal stents in long SFA lesions: the VIASTAR trial. Cardiovasc Intervent Radiol. 2015 Feb;38(1):25-32. doi: 10.1007/s00270-014-1024-9. Epub 2014 Dec 5.
Reference Type
BACKGROUND
Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, Razavi M, Reekers J, Norgren L. An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II): The TASC Steering Comittee(.). Ann Vasc Dis. 2015;8(4):343-57. doi: 10.3400/avd.tasc.15-01000. Epub 2015 Oct 23.
Reference Type
BACKGROUND
Saxon RR, Dake MD, Volgelzang RL, Katzen BT, Becker GJ. Randomized, multicenter study comparing expanded polytetrafluoroethylene-covered endoprosthesis placement with percutaneous transluminal angioplasty in the treatment of superficial femoral artery occlusive disease. J Vasc Interv Radiol. 2008 Jun;19(6):823-32. doi: 10.1016/j.jvir.2008.02.008. Epub 2008 Apr 10.
Reference Type
BACKGROUND
Rastan A, Krankenberg H, Baumgartner I, Blessing E, Muller-Hulsbeck S, Pilger E, Scheinert D, Lammer J, Beschorner U, Noory E, Neumann FJ, Zeller T. Stent placement vs. balloon angioplasty for popliteal artery treatment: two-year results of a prospective, multicenter, randomized trial. J Endovasc Ther. 2015 Feb;22(1):22-7. doi: 10.1177/1526602814564386.
Reference Type
BACKGROUND
Dick P, Wallner H, Sabeti S, Loewe C, Mlekusch W, Lammer J, Koppensteiner R, Minar E, Schillinger M. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv. 2009 Dec 1;74(7):1090-5. doi: 10.1002/ccd.22128.
Reference Type
BACKGROUND
Krankenberg H, Schluter M, Steinkamp HJ, Burgelin K, Scheinert D, Schulte KL, Minar E, Peeters P, Bosiers M, Tepe G, Reimers B, Mahler F, Tubler T, Zeller T. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation. 2007 Jul 17;116(3):285-92. doi: 10.1161/CIRCULATIONAHA.107.689141. Epub 2007 Jun 25.
Reference Type
BACKGROUND
Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Zeller T, Roubin GS, Burket MW, Khatib Y, Snyder SA, Ragheb AO, White JK, Machan LS; Zilver PTX Investigators. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011 Oct 1;4(5):495-504. doi: 10.1161/CIRCINTERVENTIONS.111.962324. Epub 2011 Sep 27.
Reference Type
BACKGROUND
Deloose K, Lauwers K, Callaert J, Maene L, Keirse K, Verbist J, Peeters P, Bosiers M. Drug-eluting technologies in femoral artery lesions. J Cardiovasc Surg (Torino). 2013 Apr;54(2):217-24.
Reference Type
BACKGROUND
Brodmann M. Prime time for drug eluting balloons in SFA interventions? J Cardiovasc Surg (Torino). 2014 Aug;55(4):461-4. Epub 2014 Jun 18.
Reference Type
BACKGROUND
Minar E, Schillinger M. Innovative technologies for SFA occlusions: drug coated balloons in SFA lesions. J Cardiovasc Surg (Torino). 2012 Aug;53(4):481-6.
Reference Type
BACKGROUND
Schmidt W, Wissgott C, Andresen R, Behrens P, Schmitz KP. Performance characteristics of modern self-expanding nitinol stents indicated for SFA. Rofo. 2011 Sep;183(9):818-25. doi: 10.1055/s-0031-1273445. Epub 2011 Jul 12.
Reference Type
BACKGROUND
Johnston CR, Lee K, Flewitt J, Moore R, Dobson GM, Thornton GM. The mechanical properties of endovascular stents: an in vitro assessment. Cardiovasc Eng. 2010 Sep;10(3):128-35. doi: 10.1007/s10558-010-9097-9.
Reference Type
BACKGROUND
Cho H, Nango M, Sakai Y, Sohgawa E, Kageyama K, Hamamoto S, Kitayama T, Yamamoto A, Miki Y. Neointimal hyperplasia after stent placement across size-discrepant vessels in an animal study. Jpn J Radiol. 2014 Jun;32(6):340-6. doi: 10.1007/s11604-014-0311-3. Epub 2014 Apr 9.
Reference Type
BACKGROUND
Zhao HQ, Nikanorov A, Virmani R, Jones R, Pacheco E, Schwartz LB. Late stent expansion and neointimal proliferation of oversized Nitinol stents in peripheral arteries. Cardiovasc Intervent Radiol. 2009 Jul;32(4):720-6. doi: 10.1007/s00270-009-9601-z. Epub 2009 May 30.
Reference Type
BACKGROUND
Freeman JW, Snowhill PB, Nosher JL. A link between stent radial forces and vascular wall remodeling: the discovery of an optimal stent radial force for minimal vessel restenosis. Connect Tissue Res. 2010 Aug;51(4):314-26. doi: 10.3109/03008200903329771.
Reference Type
BACKGROUND
Saguner AM, Traupe T, Raber L, Hess N, Banz Y, Saguner AR, Diehm N, Hess OM. Oversizing and restenosis with self-expanding stents in iliofemoral arteries. Cardiovasc Intervent Radiol. 2012 Aug;35(4):906-13. doi: 10.1007/s00270-011-0275-y. Epub 2011 Oct 18.
Reference Type
BACKGROUND
Kirsch EC, Khangure MS, Morling P, York TJ, McAuliffe W. Oversizing of self-expanding stents: influence on the development of neointimal hyperplasia of the carotid artery in a canine model. AJNR Am J Neuroradiol. 2002 Jan;23(1):121-7.
Reference Type
BACKGROUND
Vorwerk D, Redha F, Neuerburg J, Clerc C, Gunther RW. Neointima formation following arterial placement of self-expanding stents of different radial force: experimental results. Cardiovasc Intervent Radiol. 1994 Jan-Feb;17(1):27-32. doi: 10.1007/BF00197911.
Reference Type
BACKGROUND
Saxon RR, Chervu A, Jones PA, Bajwa TK, Gable DR, Soukas PA, Begg RJ, Adams JG, Ansel GM, Schneider DB, Eichler CM, Rush MJ. Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) trial. J Vasc Interv Radiol. 2013 Feb;24(2):165-73; quiz 174. doi: 10.1016/j.jvir.2012.10.004. Epub 2013 Jan 28.
Reference Type
BACKGROUND
Goueffic Y, Kaladji A, Guyomarch B, Montagne C, Fairier D, Gestin S, Riche VP, Vent PA, Chaillou P, Costargent A, Patra P. Bare metal stent versus paclitaxel eluting stent for intermediate length femoropopliteal arterial lesions (BATTLE trial): study protocol for a randomized controlled trial. Trials. 2014 Oct 30;15:423. doi: 10.1186/1745-6215-15-423.
Reference Type
BACKGROUND
Wressnegger A, Kaider A, Funovics MA. Self-expanding nitinol stents of high versus low chronic outward force in de novo femoropopliteal occlusive arterial lesions (BIOFLEX-COF trial): study protocol for a randomized controlled trial. Trials. 2017 Dec 14;18(1):594. doi: 10.1186/s13063-017-2338-0.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1026/2015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Study to Determine the Performance of the Astron and Pulsar-18 Stents in Europe
NCT01661231
UNKNOWN
NA
Safety and Effectiveness of the Peripheral Balloon-Expandable Covered Stent System for Iliac Artery Stenosis/Occlusion. (SELECT)
NCT06605209
RECRUITING
NA
Evaluation of the STARFlex® Septal Closure System in Patients With a Stroke or TIA Due to the Possible Passage of a Clot of Unknown Origin Through a Patent Foramen Ovale (PFO)
NCT00201461
UNKNOWN
PHASE2/PHASE3
Clinical Performance of the VESTO® Vascular Stent for Treatment of Iliac Peripheral Obstructive Arterial Disease
NCT06573437
RECRUITING
BIOTRONIK 4French for AMBulatory Peripheral Intervention
NCT03044002
COMPLETED
Evaluation of Efficacy of the EPIC™ Self-Expanding Nitinol Vascular Stent
NCT01336101
COMPLETED
NA
SORT-OUT VI - Randomized Clinical Comparison of Biomatrix Flex® and Resolute Integrity®
NCT01956448
COMPLETED
NA
Bare Metal Bifurcation Stent Clinical Trial in Humans
NCT00607321
COMPLETED
NA
Late Acquired Malaposition and Different Polymers
NCT02018991
COMPLETED
PHASE4
EverFlex™ Self-expanding Peripheral Stent With Entrust™ Delivery System Clinical Study
NCT02066740
COMPLETED
NA
PCI With AXXESS Biolimus A9 Eluting Bifurcation Stent in Treating Coronary Artery Bifurcation Disease
NCT02384629
WITHDRAWN
PHASE4
To Evaluate Safety and Efficacy of CGBIO Stent Compared to Biomatrix Flex Stent
NCT03089450
UNKNOWN
NA
The Isthmus Logic Post Market Clinical Follow-up Study
NCT05616143
UNKNOWN
Study on the Safety and Effectiveness of a Biodegradable Patent Foramen Ovale Occluder System
NCT07300358
NOT_YET_RECRUITING
NA
S.M.A.R.T.® Nitinol Self-Expandable Stent in the Treatment of Obstructive Superficial Femoral Artery Disease
NCT00739102
COMPLETED
NA
Evaluation of Safety and Effectiveness of the BioMimics 3D Stent System
NCT02400905
COMPLETED
NA
Evaluation of the Sinus-Venous Stent for the Treatment of Iliofemoral Venous Occlusive Disease
NCT02799914
WITHDRAWN
Endovascular Treatment of Atherosclerotic Lesions in the SFA Using the Sinus-superflex-635 Stent
NCT01816854
COMPLETED
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
NCT02900924
COMPLETED
A Study of the Temporary Spur Stent for the Treatment of Narrowing and Blockages in the Arteries Below the Knee
NCT03807531
ACTIVE_NOT_RECRUITING
NA
Sequent Please Drug Coated Balloons Versus Primary Stent Application in Long SFA Lesions
NCT03332264
COMPLETED
NA
VIVO Clinical Study
NCT01970007
COMPLETED
NA
Peripheral Venous Stent System in the Treatment of Iliac Vein Stenosis or Occlusion
NCT04812444
COMPLETED
NA
Evaluation of the Zilver® Vena™ Venous Stent
NCT01663051
COMPLETED
Physician-Initiated Trial Investigating the BeGraft Peripheral Stent Graft System
NCT02211716
COMPLETED
PHASE4